THE MICROBIOME FACTOR IN ONCOLOGY: ENHANCING DRUG EFFICACY AND REDUCING ADVERSE EFFECTS THROUGH MICROBIOTECHNOLOGICAL MODULATION

Abstract

In recent years, the gut microbiome has been increasingly recognized as a key modifiable

determinant of both the efficacy and safety of anticancer therapy. Growing clinical and experimental

evidence indicates that microbial community structure and, more importantly, functional capacity can

shape systemic immune tone, inflammatory signaling, and host–microbe metabolic outputs (including

short-chain fatty acids, tryptophan-derived metabolites, and bile acid transformation). Through these

pathways, the microbiome may influence tumor immune microenvironment features and the

likelihood of response or resistance to modern treatments, particularly immune checkpoint inhibitors

targeting PD-1/PD-L1 and CTLA-4. In parallel, the microbiome can contribute to treatment-related 

toxicity by modulating drug metabolism and mucosal immunity, thereby affecting the risk and

severity of immune-related adverse events (irAEs) and gastrointestinal complications. This article

synthesizes current mechanistic concepts and translational findings linking the microbiome to

oncologic outcomes and evaluates microbiotechnology-driven strategies for targeted microbiome

modulation, including fecal microbiota transplantation, live biotherapeutic products (defined

microbial consortia), prebiotic and postbiotic interventions, metabolite-oriented approaches, and

selective inhibition of specific bacterial enzymes as a rational route to reduce toxicity while

preserving anticancer activity. Particular attention is paid to practical barriers to implementation—

standardization, biosafety, reproducibility, regulatory requirements, and major confounders such as

antibiotic exposure, diet, and concomitant medications—which complicate causal inference and limit

broad clinical adoption. Overall, the evidence supports the promise of personalized, biomarker

informed microbiome modulation as an adjunct strategy to enhance therapeutic benefit and mitigate

adverse effects, provided that efficacy and safety are confirmed in well-controlled clinical trials.